July 07, 2023
Martin v. BioXcel Therapeutics, Inc. et al
Case Number:
3:23-cv-00915
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Grant & Eisenhofer
- Hurwitz Sagarin
- Izard Kindall
- Jacobs & Dow
- Latham & Watkins
- Levi & Korsinsky
- Lowenstein Sandler
- Ment Law Group
- Mott Zezula
- Zeisler & Zeisler
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
July 12, 2024
AI Drugmaker BioXcel Beats Investor Fraud Suit, For Now
A Connecticut federal judge has tossed a proposed securities fraud class action against BioXcel Therapeutics Inc., saying that while shareholders sufficiently alleged the AI-driven drugmaker made misleading statements concerning a dementia drug study's compliance issues, they failed to adequately plead the company intended to deceive or defraud investors.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login